Postpartum Depression Market

DelveInsight’s ‘Postpartum Depression (PPD) - Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Postpartum Depression (PPD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Postpartum Depression (PPD) market size from 2017 to 2030. The report also covers current Postpartum Depression (PPD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan


Study Period: 2017–2030

Postpartum Depression (PPD) Disease Understanding and Treatment Algorithm

Postpartum Depression (PPD) Overview

Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10–15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.


Postpartum depression usually begins within 1–12 months after delivery. In some women, post-partum blues simply continue and become more severe. In others, a period of wellbeing after delivery is followed by a gradual onset of depression. The patterns of symptoms in women with postpartum depression are similar to those in women who have depression unrelated to childbirth. Several factors can lead to postpartum depression. Women with a history of depression and other mental health conditions face a higher risk of PPD.


Postpartum Depression (PPD) Diagnosis

Women who are at risk for postpartum depression should be identified as soon as possible during pregnancy so that appropriate follow-up and care can be initiated. Risk factors for postpartum depression include depression, anxiety, stressful life events during pregnancy or the early puerperium, low levels of social support, and a personal or family history of depression. Women with a history of postpartum depression are also at increased risk of recurrence.

Screening for postpartum depression should be considered strongly, although evidence in support of universal screening tools is lacking. Patients with known risk factors may be selected for screening with the EPDS. The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-rated instrument that has been used widely to screen for postpartum depression. A reasonable cut-off on the EPDS is a score of 13 or greater, even though the sensitivity and specificity vary across languages and cultures. Patients with a score of 13 or greater should be assessed for depression; however, a special note should be made of positive responses on item 10 regarding suicidal ideation.


Postpartum Depression (PPD) Treatment

Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in the treatment of PPD. Other treatments, which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.


As in the case of other types of depression, PPD can be treated using a combination of therapy and antidepressant medications. There are other classes of medications which are being prescribed for PPD as off-label therapies. One such class of medication is known as selective serotonin reuptake inhibitors (SSRIs), which includes fluoxetine and sertraline. SSRIs relieve symptoms by blocking the reabsorption, or reuptake, of serotonin by specific nerve cells in the brain; this increases the level of available serotonin, which improves the mood of the patient. SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, and sertraline) are generally found to produce fewer side effects when compared with tricyclic antidepressants. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) has also been found useful in the treatment of PPD.


It covers the details of conventional and current medical therapies available in the PPD market for the treatment of the various types of PPD. It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight’s Postpartum Depression (PPD) market report gives a thorough understanding of Postpartum Depression (PPD) by including details such as disease introduction, causes, risk factors, pathogenesis, and diagnosis. 

Postpartum Depression (PPD) Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Maternal Postpartum Depression and Type-specific Diagnosed Prevalence of Postpartum Depression scenario of Postpartum Depression (PPD) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.


Key Findings

This section provides glimpse of the Postpartum Depression (PPD) epidemiology in the 7MM.

  • In the 7MM, the total diagnosed prevalent cases of PPD in 2017 were 1,134,800 out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which were 609,900, which is expected to increase during forecast period (2020–2030).
  • As per the estimates, in Japan the diagnosed prevalence of PPD was found to be the second highest after the US with 116,280 in 2017.


Country Wise- Postpartum Depression (PPD) Epidemiology

The epidemiology segment also provides the Postpartum Depression (PPD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Postpartum Depression (PPD) Drug Chapters

The drug chapter segment of the PPD report encloses the detailed analysis of PPD marketed drugs and mid and late stage pipeline drugs. It also helps to understand the PPD clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.


Postpartum Depression (PPD) Marketed Drugs


Zulresso (brexanolone): Sage Therapeutics

Zulresso marketed by Sage Therapeutics is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. Brexanolone was granted a priority review and was designated a breakthrough treatment by the FDA. Brexanolone is available to the patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. It is important to note that Zulresso (brexanolone) is the first drug approved by the US FDA specifically for postpartum depression in adults. Zulresso has also been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of PPD.

Product detail in the report…


Postpartum Depression (PPD) Emerging Drugs


Zuranolone (SAGE-217): Sage Therapeutics

Zuranolone (SAGE-217) by Sage Therapeutics is an investigational, oral, novel medicine in development for postpartum depression. It is given once-daily; a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), which contributes in regulating CNS function significantly.

Product detail in the report…


Ganaxolone (CCD-1042): Marinus Pharmaceuticals

Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited antiepileptic (anti-seizure), anxiolytic (anti-anxiety), and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (intravenous, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors.

Product detail in the report…


Postpartum Depression (PPD) Market Outlook

According to the American Psychiatric Association (APA), Postpartum depression (PPD) is a serious, but treatable medical illness, which involves feelings of extreme sadness, emotional liability, indifference and/or anxiety, as well as changes in energy, sleep, and appetite, and carries risks for the mother and the newborn child. PPD usually starts within the first month or any time within the first year after childbirth and can last from weeks to months. In more severe cases, it can develop into chronic episodes of depression.


Treatments include the antidepressant medications along with the new upcoming therapeutic strategies that work on the principle of GABAA receptor modulation. The medical management for PPD comprises several aspects such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. The treatment strategy also encompasses psychological and psychosocial treatments, as well as non-pharmacologic treatments. Besides, the medical care of a PDD patient and his family is incomplete without providing a support system for their psychosocial wellbeing. The current US market consists of only one approved product—Zulresso (brexanolone/SAGE-547)—to treat patients with PPD.


Zulresso, which is marketed by Sage Therapeutics, was approved by the US FDA, in March 2019.


The PPD market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted PPD market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.


This segment gives a thorough detail of PPD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, PPD 7MM market is expected to change in the study period 2017–2030.


Key Findings

This section includes a glimpse of the Postpartum Depression (PPD) 7MM market.

  • The United States accounts for the largest market size of Postpartum Depression (PPD), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
  • The market size of Postpartum Depression (PPD) in the seven major markets is USD 138.75 Million in 2017 for the study period (2017–2030).


The United States Market Outlook

This section provides the total Postpartum Depression (PPD) market size and market size by therapies in the United States.


EU-5 Market Outlook

The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Postpartum Depression (PPD) market size and market size by therapies in Japan are provided.

Postpartum Depression (PPD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression (PPD) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Postpartum Depression (PPD) market uptake by drugs; patient uptake by therapies; and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Postpartum Depression (PPD) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Postpartum Depression (PPD) emerging therapies.


Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Postpartum Depression (PPD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of Postpartum Depression (PPD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Postpartum Depression (PPD) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Postpartum Depression (PPD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Postpartum Depression (PPD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Postpartum Depression (PPD) market.

Report Highlights

  • In the coming years, Postpartum Depression (PPD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Postpartum Depression (PPD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players such as Sage Therapeutics and Marinus Pharmaceuticals are involved in developing therapies for Postpartum Depression (PPD). Launch of emerging therapies such as SAGE-217 and Ganaxolone will significantly impact the Postpartum Depression (PPD) market. Out of the two prominent emerging players Sage Therapeutics is a leading player and its potential drug SAGE-217 has shown promising results in the clinical trials for PPD.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Postpartum Depression (PPD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Postpartum Depression (PPD) Pipeline Analysis
  • Postpartum Depression (PPD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Postpartum Depression (PPD) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Postpartum Depression (PPD) Epidemiology Segmentation (Maternal as well as paternal PPD)
  • Type-specific Diagnosed Prevalence of PPD (Postpartum blues, Obsessive Compulsive Disorder post-pregnancy, Postpartum Psychosis, Posttraumatic stress disorder (PTSD) and Postpartum Panic Disorder)
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Postpartum Depression (PPD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Postpartum Depression (PPD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Postpartum Depression (PPD) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Postpartum Depression (PPD) market size during the forecast period (2020–2030)?
  • At what CAGR, the Postpartum Depression (PPD) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Postpartum Depression (PPD) market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Postpartum Depression (PPD) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Postpartum Depression (PPD)?
  • What is the historical Postpartum Depression (PPD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Postpartum Depression (PPD) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Postpartum Depression (PPD)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Postpartum Depression (PPD) during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Postpartum Depression (PPD) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Postpartum Depression (PPD) in the US and Europe?
  • What are the Postpartum Depression (PPD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Postpartum Depression (PPD)?
  • How many therapies are developed by each company for the treatment of Postpartum Depression (PPD)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Postpartum Depression (PPD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression (PPD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Postpartum Depression (PPD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Postpartum Depression (PPD)?
  • What are the 7MM historical and forecasted market of Postpartum Depression (PPD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Postpartum Depression (PPD).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Postpartum Depression (PPD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Postpartum Depression (PPD) market.
  • To understand the future market competition in the Postpartum Depression (PPD) market.


What is Postpartum Depression? 

Postpartum Depression is the most common non-psychotic, complication of childbearing affecting women and represents a significant public health problem affecting women and their families.


What was the Postpartum Depression market size in the 7 major markets (MM) in 2017? 

The market size of Postpartum Depression in the 7MM was USD 138.75 Million in 2017.


What was the total diagnosed prevalent population of Postpartum Depression in the 7MM in 2017? 

 

The total diagnosed Postpartum Depression prevalent population in the 7MM was 1,134,800 in 2017.


What are the market drivers of Postpartum Depression?

Increasing Cases, Increasing Awareness, Zulresso’s Positive Breastfeeding Data, and Improvement over Conventional Therapies are the Postpartum Depression market drivers.

 

What are the market barriers of Postpartum Depression?

Adverse Side Effects Associated with Current Therapy, Under diagnoses and Undertreatment, Lack of Proper Diagnostic Tools, and Lack of Patient Compliance are the Postpartum Depression market barriers.  


Which are the emerging therapies in the Postpartum Depression market?

Zuranolone (SAGE-217), Ganaxolone (CCD-1042) are the emerging therapies in the Postpartum Depression market


Which are the leading companies in the Postpartum Depression market? 

Sage Therapeutics, Marinus Pharmaceuticals are the leading companies in the Postpartum Depression market

 

How is epidemiology segmented for Postpartum Depression?  

Postpartum Depression epidemiology is segmented as Total Diagnosed Prevalent Population of Postpartum Depression, and Type-specific Diagnosed Prevalence of Postpartum Depression in the 7MM from 2017 to 2030.

1 Key Insights

2 Postpartum depression (PPD) Market Overview at a Glance

2.1 Market Share (%) Distribution of Postpartum depression (PPD) in 2017

2.2 Market Share (%) Distribution of Postpartum depression (PPD) in 2030

3 Disease Background and Overview: Postpartum depression (PPD)

3.1 Introduction

3.2 Clinical Presentation

3.3 Risk Factors

3.4 Pathogenesis

3.5 Diagnosis and Screening

3.5.1 Diagnostic Criteria

4 Epidemiology and Patient Population

4.1 Key Findings

4.2 7MM Total Diagnosed Prevalent Population of Postpartum Depression (PPD)

5 Country-Wise Epidemiology of Postpartum Depression (PPD)

5.1 United States

5.1.1 Assumptions and Rationale

5.1.2 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States

5.1.3 Type-specific Diagnosed Prevalence of Postpartum Depression in the United States

5.2 EU5 Countries

5.3 Germany

5.3.1 Assumptions and Rationale

5.3.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Germany

5.3.2 Type-specific Diagnosed Prevalence of Postpartum Depression in Germany

5.4 France

5.4.1 Assumptions and Rationale

5.4.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in France

5.4.2 Type-specific Diagnosed Prevalence of Postpartum Depression in France

5.5 Italy

5.5.1 Assumptions and Rationale

5.5.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Italy

5.5.2 Type-specific Diagnosed Prevalence of Postpartum Depression in Italy

5.6 Spain

5.6.1 Assumptions and Rationale

5.6.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Spain

5.6.2 Type-specific Diagnosed Prevalence of Postpartum Depression in Spain

5.7 United Kingdom

5.7.1 Assumptions and Rationale

5.7.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United Kingdom

5.7.2 Type-specific Diagnosed Prevalence of Postpartum Depression in the United Kingdom

5.8 Japan

5.8.1 Assumptions and Rationale

5.8.1 Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan

5.8.2 Type-specific Diagnosed Prevalence of Postpartum Depression in Japan

6 Treatment

6.1 Antidepressant medication

6.2 Psychological and psychosocial treatments

6.3 Non-pharmacologic treatments

6.4 Hormone therapy

7 Treatment Algorithm by American Family Physician (AFP)

8 Treatment Guidelines by Unicare

9 Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)

10 Recognized Establishments

11 Unmet Needs

12 Marketed Profile

12.1 Zulresso (brexanolone): Sage Therapeutics

12.1.1 Drug Description

12.1.2 Regulatory Milestones

12.1.3 Other Development Activities

12.1.4 Safety and Efficacy

12.1.5 Product Profile

12.2 Emerging Drugs

12.3 Key Cross Competition

12.4 Zuranolone (SAGE-217): Sage Therapeutics

12.4.1 Drug Description

12.4.2 Other Developmental Activities

12.4.3 Clinical Development

12.4.4 Safety and Efficacy

12.4.5 Product Profile

12.5 Ganaxolone (CCD-1042): Marinus Pharmaceuticals

12.5.1 Product Description

12.5.2 Other Developmental Activities

12.5.3 Clinical Development

12.5.4 Safety and Efficacy

12.5.5 Product Profile

13 Postpartum Depression: 7 Major Market Analysis

13.1 Key Findings

13.2 Market Size of Postpartum Depression in the 7MM

14 The United States Market Outlook

14.1 United States Market Size

14.1.1 Total Market size of Postpartum Depression

14.1.2 Market Size by Therapies

14.2 EU-5 Countries: Market Outlook

14.1 Germany

14.1.1 Total Market size of Postpartum Depression

14.1.2 Market Size by Therapies

14.2 France

14.2.1 Total Market Size of Postpartum Depression

14.2.2 Market Size by Therapies

14.3 Italy

14.3.1 Total Market Size of Postpartum Depression

14.3.2 Market Size by Therapies

14.4 Spain

14.4.1 Total Market Size of Postpartum Depression

14.4.2 Market Size by Therapies

14.5 United Kingdom

14.5.1 Total Market Size of Postpartum Depression

14.5.2 Market Size by Therapies

15 Japan: Market Outlook

15.1 Japan market Size

15.1.1 Total Market Size of Postpartum Depression

15.1.2 Market Size by Therapies

16 KOL Reviews

17 Case Reports

17.1. Patient Story: Postpartum Depression (American Psychiatric Association)

17.2. Case Study: The Effectiveness of Kangaroo Care for a Patient with Postpartum Depression and Comorbid Mother-Infant Bonding Disorder

18 Market Drivers

19 Market Barriers

20 SWOT Analysis

21 Appendix

21.1 Bibliography

21.2 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Table 1: Symptoms of Major Depressive Disorder

Table 2: Key Recommendations For Practice

Table 3: Depression in DSM

Table 4: DSM-V Diagnostic Criteria for Major Depressive Episode

Table 5: Total Diagnosed Prevalent Population of PPD in the 7MM (2017–2030)

Table 6: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the US (2017–2030)

Table 7: Type-specific Diagnosed Prevalence of Postpartum Depression in the US (2017–2030)

Table 8: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Germany (2017–2030)

Table 9: Type-specific Diagnosed Prevalence of Postpartum Depression in Germany (2017–2030)

Table 10: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in France (2017–2030)

Table 11: Type-specific Diagnosed Prevalence of Postpartum Depression in France (2017–2030)

Table 12: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Italy (2017–2030)

Table 13: Type-specific Diagnosed Prevalence of Postpartum Depression in Italy (2017–2030)

Table 14: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Spain (2017–2030)

Table 15: Type-specific Diagnosed Prevalence of Postpartum Depression in Spain (2017–2030)

Table 16: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the UK (2017–2030)

Table 17: Type-specific Diagnosed Prevalence of Postpartum Depression in the UK (2017–2030)

Table 18: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan (2017–2030)

Table 19: Type-specific Diagnosed Prevalence of Postpartum Depression in Japan (2017–2030)

Table 20: Commercially Available Antidepressant to use during Pregnancy or Breastfeeding

Table 21: Patents for Zulresso

Table 22: SAGE-217, Clinical Trial Description, 2020

Table 23: Ganaxolone, Clinical Trial Description, 2020

Table 24: 7 Major Market Size of Postpartum Depression in USD Million (2017–2030)

Table 25: Market Size of Postpartum Depression in the United States, in USD Million (2017–2030)

Table 26: Market size of Postpartum Depression by therapies in the United States, in USD Million (2017–2030)

Table 27: Market Size of Postpartum Depression in Germany, in USD Million (2017–2030)

Table 28: Market size of Postpartum Depression by therapies in Germany, in USD Million (2017–2030)

Table 29: Market Size of Postpartum Depression in France, in USD Million (2017–2030)

Table 30: Market size of Postpartum Depression by therapies in France, in USD Million (2017–2030)

Table 31: Market Size of Postpartum Depression in Italy, in USD Million (2017–2030)

Table 32: Market size of Postpartum Depression by therapies in Italy, in USD Million (2017–2030)

Table 33: Market Size of Postpartum Depression in Spain, in USD Million (2017–2030)

Table 34: Market size of Postpartum Depression by therapies in Spain, in USD Million (2017–2030)

Table 35: Market Size of Postpartum Depression in the United Kingdom, in USD Million (2017–2030)

Table 36: Market size of Postpartum Depression by therapies in the UK, in USD Million (2017–2030)

Table 37: Market Size of Postpartum Depression in Japan, in USD Million (2017–2030)

Table 38: Market size of Postpartum Depression by therapies in Japan, in USD Million (2017–2030)

Figure 1: Total Diagnosed Prevalent Population of Postpartum Depression in the 7MM (2017–2030)

Figure 2: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the US (2017–2030)

Figure 3: Type-specific Diagnosed Prevalence of Postpartum Depression in the US (2017–2030)

Figure 4: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Germany (2017–2030)

Figure 5: Type-specific Diagnosed Prevalence of Postpartum Depression in Germany (2017–2030)

Figure 6: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in France (2017–2030)

Figure 7: Type-specific Diagnosed Prevalence of Postpartum Depression in France (2017–2030)

Figure 8: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Italy (2017–2030)

Figure 9: Type-specific Diagnosed Prevalence of Postpartum Depression in Italy (2017–2030)

Figure 10: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Spain (2017–2030)

Figure 11: Type-specific Diagnosed Prevalence of Postpartum Depression in Spain (2017–2030)

Figure 12: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the UK (2017–2030)

Figure 13: Type-specific Diagnosed Prevalence of Postpartum Depression in the UK (2017–2030)

Figure 14: Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan (2017–2030)

Figure 15: Type-specific Diagnosed Prevalence of Postpartum Depression in Japan (2017–2030)

Figure 16: Pharmacologic Treatment of Postpartum Major Depression

Figure 17: Unmet Needs of PPD

Figure 18: 7 Major Market Size of Postpartum Depression in USD Million (2017–2030)

Figure 19: Market Size of Postpartum Depression in the United States, USD Millions (2017–2030)

Figure 20: Market size of Postpartum Depression by therapies in the United States, in USD Million (2017–2030)

Figure 21: Market Size of Postpartum Depression in Germany, USD Million (2017–2030)

Figure 22: Market Size of Postpartum Depression by therapies in Germany, in USD Million (2017–2030)

Figure 23: Market Size of Postpartum Depression in France, USD Million (2017–2030)

Figure 24: Market Size of Postpartum Depression by therapies in France, in USD Million (2017–2030)

Figure 25: Market Size of Postpartum Depression in Italy, USD Million (2017–2030)

Figure 26: Market Size of Postpartum Depression by therapies in Italy, in USD Million (2017–2030)

Figure 27: Market Size of Postpartum Depression in Spain, USD Million (2017–2030)

Figure 28: Market Size of Postpartum Depression by therapies in Spain, in USD Million (2017–2030)

Figure 29: Market Size of Postpartum Depression in the United Kingdom, USD Million (2017–2030)

Figure 30: Market Size of Postpartum Depression by therapies in the United Kingdom, in USD Million (2017–2030)

Figure 31: Market Size of Postpartum Depression in Japan, USD Million (2017–2030)

Figure 32: Market Size of Postpartum Depression by therapies in Japan, in USD Million (2017–2030)

Figure 33: Market Drivers

Figure 34: Market Barriers

Figure 35: Postpartum Depression SWOT Analysis

Sage Therapeutics

Marinus Pharmaceuticals

  • Tags:
  • Postpartum Depression market
  • Postpartum Depression market resear...
  • Postpartum Depression market insigh...
  • Postpartum Depression market trends
  • Postpartum Depression market foreca...
  • Postpartum Depression market share
  • Postpartum Depression pipeline drug...
  • Postpartum Depression treatment alg...
  • Postpartum Depression drugs
  • Postpartum Depression sales forecas...
  • Postpartum Depression market size
  • Postpartum Depression disease
  • Postpartum Depression epidemiology
  • Postpartum Depression

Forward to Friend

Need A Quote